Assembly Biosciences, Inc. Additional Paid in Capital, Common Stock
Assembly Biosciences, Inc. (ASMB) had Additional Paid in Capital, Common Stock of $1.15 billion as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-13
- 2026-06-30: Additional Paid in Capital, Common Stock $1.15B.
- 2026-03-31: Additional Paid in Capital, Common Stock $1.04B.
- 2025-12-31: Additional Paid in Capital, Common Stock $1.04B.
- 2025-09-30: Additional Paid in Capital, Common Stock $1.04B.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $1.15B 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $1.04B 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $1.04B 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $1.04B 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $863.31M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $862.12M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $859.49M 10-K · filed 2026-03-19 | |
| 2024-09-30 | $841.74M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $840.95M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $827.66M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $826.92M 10-K · filed 2025-03-20 | |
| 2023-09-30 | $816.72M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $815.59M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $814.26M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $807.98M 10-K · filed 2024-03-28 | $807.94M 10-K · filed 2023-03-22 |
| 2022-09-30 | $805.48M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $803.91M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $802.17M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $800.73M 10-K · filed 2023-03-22 | |
| 2021-09-30 | $796.06M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $784.39M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $776.25M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $742.39M 10-K · filed 2022-03-11 | |
| 2020-09-30 | $732.83M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $725.78M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $717.90M 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $712.81M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $569.00M 10-Q · filed 2019-11-07 | |
| 2018-12-31 | $552.76M 10-K · filed 2020-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |